BioXcel Therapeutics secures USD 77.25 million DIP financing from Oaktree, Qatar Investment Authority affiliates

• BioXcel Therapeutics entered a super-priority senior secured priming debtor-in-possession credit agreement with Oaktree affiliates and Qatar Investment Authority affiliates.
• DIP facility totals up to $77.25 million, including up to $19 million of new money term loans.
• Facility also includes up to $58.25 million of roll-up loans converting prepetition debt, including a $1.25 million bridge loan.
• Borrowings carry a 13% interest rate; roll-up interest capitalizes; 4% exit fee payable on repayment or prepayment.
• Matures Jan. 27, 2027; proceeds fund Chapter 11 working capital and case costs; lenders receive superpriority claims and priming liens.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioXcel Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-104106), on September 01, 2026, and is solely responsible for the information contained therein.